Comparing Stocks: Pediatrix Medical Group vs. Amarantus Bioscience

Investors are weighing the merits of two medical companies, Pediatrix Medical Group (NYSE: MD) and Amarantus Bioscience (OTCMKTS: AMBS), in a bid to determine which stock offers a more favorable investment opportunity. A comparative analysis of both firms reveals differences in profitability, volatility, institutional ownership, and earnings.

Pediatrix Medical Group has established itself in the market with a beta of 0.73, indicating its stock price is 27% less volatile than the S&P 500. In contrast, Amarantus Bioscience exhibits a beta of 1.59, suggesting its share price is 59% more volatile. This significant difference in volatility may influence investment decisions, particularly for risk-averse investors.

Institutional and Insider Ownership

The ownership distribution of shares provides insights into the confidence of institutional investors in these companies. An impressive 97.7% of Pediatrix Medical Group’s shares are held by institutional investors. This high level of institutional ownership often indicates a strong belief among large investors that the company will perform well over time. In contrast, Amarantus Bioscience has a modest 10.3% of its shares held by insiders, which may reflect differing levels of confidence or investment strategies.

Performance Metrics and Profitability

When examining earnings and valuation, Pediatrix Medical Group outperforms Amarantus Bioscience in several key areas. Although Amarantus records higher earnings, it falls short on revenue figures compared to its competitor. This suggests that while Amarantus may have a profitable product pipeline, Pediatrix benefits from a more stable revenue base.

Profitability metrics further illustrate the competitive landscape. Pediatrix Medical Group surpasses Amarantus Bioscience in 8 out of 11 evaluated factors, indicating a stronger overall financial health and operational efficiency.

About Pediatrix Medical Group

Founded in 1979 and headquartered in Sunrise, Florida, Pediatrix Medical Group specializes in providing neonatal, maternal-fetal, and pediatric subspecialty care services across the United States. The company offers a range of critical services, including neonatal care for premature infants, maternal-fetal care for expectant mothers, and pediatric cardiology services for children with congenital heart defects. In July 2022, the company rebranded from its former name, MEDNAX, Inc., to better reflect its core mission and services.

About Amarantus Bioscience

On the other hand, Amarantus Bioscience Holdings, Inc., founded in 2008 and based in New York, New York, focuses on developing diagnostic and therapeutic products aimed at addressing conditions in neurology, psychiatry, ophthalmology, and regenerative medicine. Among its notable diagnostic products in development is the LymPro test, designed to diagnose Alzheimer’s disease, and MSPrecise, a DNA sequencing assay for multiple sclerosis patients.

Amarantus is also advancing various therapeutic candidates, including Eltoprazine for Parkinson’s disease and a cell therapy-based product, Engineered Skin Substitute, for severe burns. The company has established partnerships, including a cooperative research agreement with the U.S. Army Institute of Surgical Research and Rutgers University.

In summary, potential investors may find that Pediatrix Medical Group presents a more stable investment opportunity with its lower volatility and higher institutional ownership. Conversely, Amarantus Bioscience may appeal to those seeking exposure to high-risk, high-reward biopharmaceutical innovations.